Investor Services
CORPORATE ACTION DETAILS

 
INDEVUS CVR SUPPRELIN (BROKERS)
Click on link for offer below to view more detail.

If review of the information provided here does not answer a particular question or concern that you may have, please do not hesitate to contact our Shareholder Services Department via any of the means listed on the "Contact us" page (accessible from the upper toolbar).
 
CSR CONVERSION

PURSUANT TO THE VALERA/INDEVOUS MERGER, THE "SUPPRELIN"
CONTINGENT VALUE RIGHTS ARE CONVERTIBLE INTO COMMON STOCK.
EACH BROKER AND REGISTERED SHAREHOLDER MUST SIGN THE FORM OF NOTICE AND SUBMIT IT TO AST IN ORDER TO RECEIVE THEIR INDEVOUS STOCK.

THE CVR IS CONVERTIBLE UNTIL APRIL 18 2012.
THE UNDERLYING SHARES WILL NOT BE SENT VIA DWAC.
RATE: 0.141. CIL: $7.0930.
 
Related Files (Click on link to open/download file)
VALERA SUPPRELIN CSR FORM OF NOTICE TO BROKERS AND SHAREHOLDERS
 
Historic Dividends